AbbVie
Oct 04, 2016
FDA Approves STELARA; Novartis announces AMG 334; AbbVie’s HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction
FDA Approves Janssen's STELARA for the Treatment of Adults With Moderately to Severely Active Crohn’s Disease Janssen Biotech Inc. received approval from the U.S. FDA for STELARA (ustekinumab), used for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older). The drug is for the ...
Read More...
Aug 24, 2016
Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer
Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer...
Read More...
Jul 25, 2014
Oncology Therapeutics Making Big in Coming Years
The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
